- First-in-class oncology therapeutic candidate YIV-906 applies an integrative systems biology approach to turn cold tumors hot - YIV-906 could increase.
Amid the whirlwind of changes to campus life during the early days of COVID-19, the Yale Center for Genome Analysis was among a handful of Yale facilities with the specialized technology necessary to investigate the biological and chemical functions and mechanisms at play within the virus. In an interview, Shrikant Mane director of the center and of the Keck Biotechnology Resource Laboratory, and professor of genetics discussed the center’s COVID-19 research.
Early in the pandemic, Alison Galvani, Burnett and Stender Families Professor of Epidemiology and director of the Center for Infectious Disease Modeling and Analysis, and her team began analyzing various scenarios for COVID-19’s spread in the U.S. and how self-isolation rates by symptomatic individuals could affect demand for Intensive Care Unit (ICU) beds. In early April she discussed the urgency of self-isolation even for those who were even “mildly symptomatic.”